STING1 and neoplasm: CD44×PD‐L1/CD3 trispecific T‐cell nanoengager loaded with the STING agonist c‐di‐AMP (CDA) (PmTriTNE@CDA) shows tumor‐specific accumulation and the preferentially unmasked in response to the weakly acidic TME to avoid on‐target off‐tumor toxicity.